$AIM Income Statement | Understand Stock

$AIM

$0.16 +$0.01 (4.8%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues:
Clinical treatment programs – US
Clinical Treatment Programs - US
Total clinical treatment programs – US

Total Revenues
Costs and Expenses:
Production costs
Research and development
General and administrative
Impairment of assets
Total Costs and Expenses

Operating loss
(Loss) gain on investments
Interest and other income
Extinguishment of financing obligation
Interest expense
Gain on sale of fixed assets
Issuance cost
Loss on warrant issuance
Change in fair value of warrants
Loss from sale of income tax operating losses
Net Loss
Reclassification adjustment for realized investment loss
Change in unrealized loss on marketable securities available for sale
Net comprehensive loss
Basic and diluted loss per share
Weighted average shares outstanding basic and diluted
Basic loss per share
Diluted loss per share
Weighted average shares outstanding basic
Weighted average shares outstanding diluted

Comments